Biopharma companies are increasingly prioritising CDMOs that can offer end-to-end capabilities across development, manufacturing, and fill-finish within a single partnership model. This shift is driven by the need to reduce complexity, accelerate timelines, and minimise operational risk.
Biopharma companies are prioritizing:
- fewer external partners
- faster tech transfer
- end-to-end service offerings
- reduced operational risk
Key Drivers:
- Cost pressure across biotech markets
- Reduced venture funding availability
- Pressure to accelerate clinical milestones
- Increased manufacturing complexity
- Demand for operational efficiency
CDMOs Expanding Integrated Offerings:
- Catalent
- AGC Biologics
- FUJIFILM Diosynth Biotechnologies
- Curia
- Recipharm
- Rentschler Biopharma
- Richter-Helm BioLogics
- Polpharma Biologics
- KBI Biopharma
- Samsung Biologics
What This Means for Sponsors
Integrated CDMOs are becoming strategic extensions of biotech organizations rather than transactional vendors. The ability to provide development, manufacturing, analytical, and regulatory services under one platform is becoming a major competitive differentiator.
